Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About

DSM-Firmenich Acquires Postbiotics Pioneer Adare Biome

Published July 4, 2023
Published July 4, 2023
Frank Flores via Unsplash

DSM-Firmenich has acquired Adare Biome, a pioneer in developing and manufacturing postbiotics, from Adare Pharma Solutions, a global technology-driven CDMO.

WHO: Adare Biome’s origins date back to 1907, when French chemist Dr. Pierre Boucard launched the branded gut supplement Lactéol, available over the counter in 35 countries and one of the most scientifically well-documented microorganism-based therapeutics.

Adare Pharma Solutions is a global, technology-driven CDMO providing product development through commercial manufacturing expertise, with a focus on oral dosage forms for the pharmaceutical industry. Adare's specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions.

As innovators in nutrition, health, and beauty, DSM-Firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances with a comprehensive range of solutions with natural and renewable ingredients and renowned science and technology capabilities. DSM-Firmenich is a Swiss-Dutch company with operations in almost 60 countries and worldwide team of nearly 30,000 employees.

WHY: DSM-Firmenich intends to extend the availability of Lactéol, Adare Biome's over-the-counter postbiotic supplement, through its B2C unit, i-Health. The acquisition of Adare Biome will also position DSM-Firmenich as a leader in the growing microbiome management market.

IN THEIR OWN WORDS: Tom Sellig, CEO of Adare Pharma Solutions, commented, "DSM-Firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics. They have the infrastructure, together with strong commercialization and science capabilities, to scale the significant scientific research that we've achieved over the years. This divestiture will provide Adare Pharma Solutions with additional resources for our core CDMO business and allow us to further grow our position as a world-class outsourcing partner to the pharmaceutical industry."

Philip Eykerman, DSM-Firmenich's President Health, Nutrition & Care, said: "Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for DSM-Firmenich that will complement three of our four Business Units. The Adare Biome teams bring great knowledge in this area which will greatly help in driving our 'Health from the Gut' strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals. We are excited to welcome the Adare Biome people to the DSM-Firmenich family and about the new opportunities this move will unlock. DSM-Firmenich's strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world."


  • DSM-Firmenich acquires Adare Biome from Adare Pharma Solutions.
  • The transaction represents an enterprise value of €275 million ($300 million), an estimated 2023 EV/EBITDA multiple of 18x.

2 Article(s) Remaining

Subscribe today for full access